Advancing Alternatives at FDA

Suzanne C Fitzpatrick, PhD, DABT, ERT
US Food and Drug Administration
ICCVAM Public Workshop
May 27, 2021

FDA Encourages the Use of New Testing Methodologies

- FDA and regulators worldwide will incorporate new testing methodologies into regulatory standards if certain standards are met
- Important to ensure regulator's familiarity with techniques before they see it in a regulatory submission
- Any technology considered for regulatory use has to be proven to be reliable, robust, reproducible, fit the context of use, etc.

FDA's Roadmap: Framework for Incorporating Emerging Predictive Toxicology Methods in Regulatory Reviews



Alternative Methods Working Group (AMWG)

- Under Office of Chief Scientist (OCS), Office of Commissioner; members from each Center and OCS
- Discuss alternative activities across FDA for use in toxicity and efficacy assessment
- Interact with U.S. federal and global partners to facilitate discussion, development, and acceptance of regulatory performance criteria for such assays
- Updates are on FDA Alternatives website (https://www.fda.gov/science-research/about-science-research-fda/advancing-alternative-methods-fda)
- Comments to FDA at alternatives@fda.hhs.gov

Here now

- FDA now has an external webpage entitled **Advancing Alternative Methods at FDA**
- Essentially a webpage for the Alternatives Methods Working Group
  - Objectives
- Information on the FDA Webinar Series on Alternative Methods
- Page will be updated periodically
- Contact information: alternatives@fda.hhs.gov



Advancing Alternative Methods at FDA

Advancing Alternative Methods at FDA

FDA's Alternative Methods Working Group

Background

Advances in systems biology, stem cells, engineered tissues, and mathematical modeling are creating unique opportunities to improve FDA's predictive ability, potentially enhancing our ability to predict risk and efficacy.

These advances may help bring FDA-regulated products to market faster, with improved efficacy, or prevent products with increased toxicological risk from reaching the market. Also critical is the potential for these advances to replace, reduce, and/or refine animal testing.

FDA has had a long-standing commitment to promote the development and use of new technologies to better predict human and animal responses to substances relevant to its regulatory mission. As part of efforts to strengthen that commitment, FDA launched its Alternative Methods Working Group (Alternative Methods Group).

FDA invites developers to showcase their cutting-edge technologies in FDA Webinar Series on Alternative Methods (/science-research/about-science-research-fda/fda-webinar-series-alternative-methods-showcasing-cutting-edge-technologies-disease-modeling)

FDA's Alternative Methods Group focuses on opportunities for evolving and innovative technologies to advance useful tools as well as new areas of science to support alternative methods to traditional toxicity and efficacy testing that extend across FDA's product areas.

It also acts as a catalyst to foster the development and potential application of alternative systems (in vitro, in vivo, in silico, and systems toxicology modeling), such as microphysiological systems, to support decision-making in regulatory toxicology.

The Alternative Methods Group facilitates interactions with global regulatory bodies interested in implementing alternative methods in toxicology. Additionally, it examines opportunities and viable ways by which emerging methods and new technologies can support regulatory review of risk, safety, and efficacy of FDA-regulated products.

The activities of FDA's Alternative Methods Group are informational and do not serve as official regulatory guidance.

Objectives of FDA's Alternative Methods Working Group

- Discuss FDA-wide new in vitro, in vivo, and in silico methods, including research, training, and communication.

FDA Office of the Chief Scientist Webinar Series on Alternative Methods

- Opportunity for developers to present new methods and methodologies to FDA.
- Webinars will be held monthly and advertised to all FDA scientists exclusively.
- If selected, developers' participation in FDA's webinar series would not constitute the agency's endorsement of a new method or methodology.
- Nor would it mean that FDA would assist the developer in qualifying his/her new method for regulatory use.

U.S. FOOD & DRUG

Home / Science & Research / About Science & Research at FDA / FDA Webinar Series on Alternative Methods: Showcasing cutting-edge technologies for disease modeling, efficacy, and safety

FDA Webinar Series on Alternative Methods: Showcasing cutting-edge technologies for disease modeling, efficacy, and safety

Share Tweet LinkedIn Email Print

About Science & Research at FDA
Emerging Sciences
Public Access to Results of FDA-Funded Scientific Research
Scientific Integrity at FDA
FDA Sexual Harassment Policy Concerning Intramural Research
Medical Product Development Tools at FDA
Advancing Alternative Methods at FDA
FDA's Predictive Toxicology Roadmap
FDA Grand Rounds
The FDA Science Forum

Promoting cutting-edge technologies for disease modeling, efficacy, and safety

Content current as of: 06/23/2020

Topic(s)
Public Awareness

FDA's **Office of the Chief Scientist** is launching a webinar series on Alternative Methods as part of FDA's commitment to promote novel technologies and potentially incorporate them into its regulatory review, as applicable.

An Opportunity for Developers and FDA Scientists

Continuing education in new predictive in vitro, in vivo, and in silico methods is vital to ensuring that FDA regulators and researchers have a broad skill set and remain current with cutting-edge science and technology. To that end, *FDA's Alternative Methods Webinar Series* will give developers the opportunity to present their new methods and methodologies exclusively to FDA scientists.

How to be Considered for Selection

To be considered for selection, please submit the following information to FDA at:

Alternatives@fda.hhs.gov

1. A description of your new method or methodology, including origin of cells (if appropriate), species of animal (if appropriate), etc.
2. A description of the proposed context of use of your new method or methodology.
3. A description of the regulatory issue/gap where it could have an impact on an important regulatory issue.
4. Data from use of your method, including any publications.

Your participation in this webinar would mean that your new technology would be introduced to FDA and that individual FDA programs would have the option to contact you for further information. However, your participation in FDA's webinar series would not constitute FDA's endorsement of your new method or methodology. Nor would it mean that FDA would assist you in qualifying your new method for regulatory use.

FDA will respond within 60 days to your webinar submission, with either a request for more information, a potential time for your webinar, or a reason why your new technology might not qualify for this program. Although every new technology is exciting to FDA, it

FDA Office of the Chief Scientist Webinar Series on Alternative Methods

How to be Considered for Selection

To be considered for selection, please submit the following information to FDA at:

Alternatives@fda.hhs.gov

1. A description of your new method or methodology, including origin of cells (if appropriate), species of animal (if appropriate), etc.
2. A description of the proposed context of use of your new method or methodology.
3. A description of the regulatory issue/gap where it could have an impact on an important regulatory issue.
4. Data from use of your method, including any publications.

Advancing Alternative Methods at FDA Webpage

Publications

An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation

Strategies for Rapid Risk Assessment of Color Additives Used in Medical Devices

An In Vitro Blood Flow Loop System for Evaluating the Thrombogenicity of Medical Devices and Biomaterials

Simultaneous UHPLC-MS/MS Method of Estradiol Metabolites to Support the Evaluation of Phase-2 Metabolic Activity of Induced Pluripotent Stem Cell Derived Hepatocytes

Liver Microphysiological Systems for Predicting and Evaluating Drug Effects

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes

Use of high-throughput enzyme-based assay with xenobiotic metabolic capability to evaluate the inhibition of acetylcholinesterase activity by organophosphorous pesticides

Assessment of Intestinal absorption of 3-MCPD by Caco-2 cells

Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development

Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method

AMWG Case Study – *In vitro* Micro physiological Systems

- Define agreed-upon terminology for MPS and research/regulatory gaps for which MPS may be useful.
- Identify partnerships to advance MPS technology.
- Develop draft performance criteria for MPS and discuss internally and then with stakeholders
- Develop mechanisms to request information from MPS developers and end users

History of FDA's Involvement with MPS

- 2010: FDA and NIH Common Fund awarded grant money to Wyss to develop a heart-lung micromachine
- 2011: DARPA approached FDA's Office of the Chief Scientist requesting to work together to develop a human body on a chip for medical countermeasures. DARPA funded MPS research and involved the FDA from the beginning of the MPS program to help ensure that regulatory challenges of reviewing drug safety and efficacy are considered during development of the MPS platform
- 2012: NCATS funded the Tissue Chip Development Program. FDA has been a partner throughout the program
- And the rest is MPS history!
- **IMPORTANT LESSON-Critical to have regulators at the table from the beginning if aim is to use method for regulatory use**



FDA Draft Definitions

Microphysiological System (MPS): A microphysiological system is an in vitro platform composed of cells; explants derived from tissues/organs; and/or organoid cell formations of human or animal origin in a micro-environment that provides and supports biochemical/electrical/mechanical responses to model a set of specific properties that define organ or tissue function.

Organ-on-a-chip: Organ-on-a-chip is a miniaturized physiological environment engineered to yield and/or analyze functional tissue units capable of modeling specified/targeted organ-level responses.

Feedback welcome: **Alternatives@fda.hhs.gov**

FDA Internal Research- FDA User Group

FDA scientists are developing in-house MPS and collaborating with several external partners

FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation

POSTED OCT 2017

London, UK, October 26 2017: CN Bio Innovations Limited announced today that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research.

Center for Drug Evaluation and Research

TISSUSE Emulating Human Biology

National Center for Toxicological Research

Center for Biologics Evaluation and Research

Original Report

Adaptation of a Simple Microfluidic Platform for High-Dimensional Quantitative Morphological Analysis of Human Mesenchymal Stromal Cells on Polystyrene-Based Substrates

SLAS Technology 2017, Vol. 22(6) 646–661 © 2017 Society for Laboratory Automation and Screening DOI: 10.1177/2472630317726050 journals.sagepub.com/home/jls SAGE

Johnny Lam[1], Ross A. Marklein[1], Jose A. Jimenez-Torres[2], David J. Beebe[2], Steven R. Bauer[1], and Kyung E. Sung[1]

Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications

Anurag Mathur[1,2], Peter Loskill[1,2], Kaifeng Shao[1], Nathaniel Huebsch[4,5], SoonGweon Hong[1], Sivan G. Marcus[1], Natalie Marks[1], Mohammad Mandegar[4,5], Bruce R. Conklin[4,5], Luke P. Lee[1,3] & Kevin E. Healy[1,2]

Center for Food Safety and Applied Nutrition

FDA and Emulate sign a Collaborative Agreement
October 29, 2020

FDA's Alternative Report

Released January 5, 2021

Context of Use Qualification

- Beyond analytical validation, what steps need to be taken to enable regulatory use, without proving utility each time?
- FDA developed concept of “qualification:” a conclusion that the results of an assessment using the model or assay can be relied upon to have a specific interpretation and application in product development and regulatory decision-making
- Inextricable to qualification is concept of “context of use:” a clearly articulated description delineating the manner and purpose of use for a particular approach

Start with a Regulatory Question-Context of use

- What question needs to be answered and for what purpose?
  - How much “validation/qualification” is needed for a particular assay will depend on the particular context of use.

- Helps define acceptable applicability domain and limitations
- Context could be expanded over time
- Choice of Reference Chemicals Related to Context of Use

FDA Encourages Stakeholder Dialogue

- FDA Stakeholders are encouraged to discuss with FDA the potential use of MPS and other new predictive methodologies for toxicity and efficacy of FDA-regulated products. Venues include:
  - AMWG webinars-see FDA Alternatives Webpage
  - Meetings such as this NASEM Meeting
  - Other Joint Meetings on MPS
  - By email –alternatives@fda.hhs.gov
  - Pre-IND/IDE meetings/written responses with FDA regulators
  - Critical Path Innovation Meetings – outside of a regulatory application

Remember-Change Takes Time- But It will Happen If We All Work Together


FDA
U.S. FOOD & DRUG
ADMINISTRATION